UBS has upgraded Sanofi to a 'Buy' rating with a target price of 110 euros, citing the neurodermatitis drug Dupixent as a key growth driver for the company in the third quarter. Analyst Carl Walton anticipates that growth will accelerate further in 2025.
UBS has maintained a "Buy" rating for Sanofi, setting a price target of 110 euros ahead of the company's upcoming financial results. Analyst Carl Walton highlighted that the neurodermatitis drug Dupixent is expected to drive growth for the pharmaceutical firm in the third quarter, with acceleration anticipated in 2025.
UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 110 euros ahead of the company's quarterly results due on October 25. Analyst Jo Walton highlighted the importance of the ongoing success of Dupixent and the market acceptance of Beyfortus.
Sanofi is investing 300 million euros for a 16% stake in a new joint venture with Orano Med to develop radiopharmaceuticals targeting rare cancers, particularly using the radioisotope lead-212. This partnership aims to leverage expertise in biopharma and nuclear technology to advance cancer treatment. The joint venture is valued at 1.9 billion euros, following Sanofi's recent licensing of an experimental drug for neuroendocrine tumors.
UBS has maintained a 'Buy' rating for Sanofi, setting a target price of 110 euros ahead of the company's quarterly results due on October 25. Analyst Jo Walton emphasized the importance of assessing the sustainability of Dupixent's success and the market acceptance of Beyfortus.
UBS has maintained a "Buy" rating for Sanofi, setting a target price of 110 euros ahead of the quarterly results due on October 25. Analyst Jo Walton will focus on the sustainability of Dupixent's success and the market acceptance of Beyfortus.
GITEX GLOBAL's DIGI_HEALTH 5.0 in Dubai showcased transformative digital health innovations, including AI-driven solutions and smart contact lenses, highlighting the UAE's commitment to advancing its digital health ecosystem. Industry leaders discussed AI's role in enhancing patient care, with significant advancements in robotics, genomics, and remote monitoring technologies. The event also announced plans for a future expo-summit in Thailand, aimed at addressing the growing demands of the digital health industry in Asia.
Argus has issued "buy" ratings for several pharmaceutical stocks, including Sanofi (SNY) with a $60 price target, Gilead Sciences (GILD) at $85, and GSK at $45. The sector is projected to grow significantly, driven by oncology sales, with companies like Johnson & Johnson and Merck also highlighted for their strong pipelines and dividend yields.
GSK announced positive results from two Phase 3 trials of its antibody drug depemokimab for chronic rhinosinusitis with nasal polyps (CRSwNP), showing significant suppression of nasal polyp growth and improved nasal obstruction compared to placebo. The drug, which targets IL-5, is also being studied for asthma and other inflammatory diseases, with potential peak annual sales exceeding £3 billion if approved. Detailed trial results will be presented at an upcoming scientific congress.
The FDA has approved Pfizer's Hympavzi for treating hemophilia A and B in patients aged 12 and older without inhibitors. This weekly injection reduces the activity of tissue factor pathway inhibitor, enhancing blood clotting. Hympavzi offers a new treatment option alongside gene therapies and other factor replacement drugs, showing superior results in lowering bleeding rates.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
